Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review

Mycoses

Volumn 60, Issue 10, 2017, Pages 626-633

  Markantonatou, Anthi Marina ^a   Ioakimidou, Aliki ^a   Arvaniti, Kostoula ^b   Manou, Eleni ^b   Papadopoulos, Vassilios ^b   Kiriklidou, Parthena ^b   Samaras, Konstantinos ^a   Kioumi, Anna ^b   Vyzantiadis, Timoleon Achilleas ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Aspergillus fumigatus; co infection; non HIV patients; Pneumocystis jirovecii; Pneumocystis pneumonia

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; CEFUROXIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GALACTOMANNAN; GANCICLOVIR; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MOXIFLOXACIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VORICONAZOLE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUNG ASPERGILLOSIS; MALE; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NESTED POLYMERASE CHAIN REACTION; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; X-RAY COMPUTED TOMOGRAPHY; AIDS RELATED COMPLEX; ASPERGILLUS FUMIGATUS; COMPLICATION; FEMALE; IMMUNOCOMPROMISED PATIENT; LUNG; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PNEUMOCYSTIS CARINII; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ASPERGILLUS FUMIGATUS; COINFECTION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INVASIVE FUNGAL INFECTIONS; LUNG; MALE; MIDDLE AGED; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDIES; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85021399119     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12642     Document Type: Review

References (40)

1. Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):5-14.
2. Jones JL, Hanson DS, Dworkin MS et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999;48:1-22.
3. Kelley CF, Checkley W, Mannino DM et al. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005). Chest. 2009;136:190-197.
4. Buchacz K, Baker RK, Palella FJ Jr et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. 2010;24:1549-1559.
5. Morris A, Norris ΚΑ. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012;25:297-317.
6. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999;353:1293-1298.
7. Enomoto T, Azuma A, Kohno A et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2010;15:126-131.
8. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.
9. Mansharamani NG, Garland R, Delaney D et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704-711.
10. Festic E, Gajic O, Limper AH et al. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128:573-579.
11. Torres HA, Chemaly RF, Storey R et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25:382-388.
12. Matsumura Y, Shindo Y, Iinuma Y et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.
13. Monnet X, Vidal-Petiot E, Osman D et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care. 2008;12:R28.
14. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18:793-806.
15. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.
16. Boonsarngsuk V, Sirilak S, Kiatboonsri S. Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors. Int J Infect Dis. 2009;13:59-66.
17. Radhi S, Alexander T, Ukwu M et al. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118.
18. Walzer PD, Evans HE, Copas AJ et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46:625-633.
19. Kim SJ, Lee J, Cho YJ et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69:88-95.
20. Baumann S, Reinwald M, Haghi D et al. Coinfection of Pneumocystis jirovecii and invasive pulmonary aspergillosis in an immunocompromised patient: a diagnostic challenge. Onkologie. 2013;36:582-584.
21. Hagiya H, Miyake T, Kokumai Y et al. Co-infection with invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonia after corticosteroid therapy. J Infect Chemother. 2013;19:342-347.
22. Kaira K, Shinomiya Y, Takahashi Y et al. Coinfection of invasive pulmonary aspergillosis and pneumocystis jiroveci pneumonia in a non-HIV patient. Acta Med Okayama. 2007;61:235-238.
23. Lee T, Bae YJ, Park SK et al. Severe pneumonia caused by combined infection with Pneumocystis jiroveci, parainfluenza virus type 3, cytomegalovirus, and Aspergillus fumigatus in a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2010;90:625-629.
24. Mariñosa M, Soler A, Nogués X et al. Pulmonary coinfection by Pneumocystis carinii and Aspegillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate. Clin Rheumatol. 2004;23:555-556.
25. Péron J, Derbel O, Penet AS et al. Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma. Pancreas. 2013;42:178-180.
26. Saito T, Shime N, Itoh K et al. Disseminated aspergillosis following resolution of Pneumocystis pneumonia with sustained elevation of beta-glucan in an Intensive Care Unit: a case report. Infection. 2009;37:547-550.
27. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523-531.
28. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust. 1995;162:233-235.
29. Vernovsky I, Dellaripa PF. Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features. J Clin Rheumatol. 2000;6:94-101.
30. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5:41-59.
31. Limper AH, Offord KP, Smith TF et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204-1209.
32. Bollée G, Sarfati C, Thiéry G et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305-1310.
33. Alanio A, Hauser PM, Lagrou K et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2386-2396.
34. Fan LC, Lu HW, Cheng KB et al. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One. 2013;8:e73099.
35. Lu Y, Ling G, Qiang C et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol. 2011;49:4361-4363.
36. Sokulska M, Kicia M, Wesołowska M et al. Pneumocystis jirovecii—from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114:3577-3585.
37. Maschmeyer G, Helweg-Larsen J, Pagano L et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71:2405-2413.
38. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1-52.
39. Segal BH, Freifeld AG, Baden LR et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008;6:122-174.
40. Maertens J, Cesaro S, Maschmeyer G et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397-2404.